Aytu BioScience (AY20) Financial Statements
Aytu BioScience Financial Overview
Aytu BioScience's market cap is currently $18.72M. The company's EPS TTM is $-1.16; its P/E ratio is -1.41; Aytu BioScience is estimated to report earnings on November 16, 2026, and the estimated EPS forecast is $-0.23. See an overview of income statement, balance sheet, and cash flow financials.
| Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 57.57M | $ 66.38M | $ 65.18M | $ 107.40M | $ 96.67M |
| Gross Profit | $ 36.82M | $ 45.83M | $ 49.05M | $ 66.63M | $ 50.28M |
| Operating Income | $ -8.31M | $ -7.83M | $ -1.59M | $ -17.07M | $ -109.91M |
| EBITDA | $ -4.38M | $ -4.67M | $ 1.41M | $ -3.27M | $ -27.96M |
| Net Income | $ -14.25M | $ -13.56M | $ -15.84M | $ -17.05M | $ -108.78M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 26.31M | $ 30.95M | $ 20.01M | $ 22.98M | $ 19.36M |
| Total Assets | $ 105.01M | $ 124.18M | $ 118.86M | $ 137.84M | $ 137.62M |
| Total Debt | $ 18.11M | $ 22.94M | $ 16.42M | $ 30.43M | $ 18.19M |
| Net Debt | $ -8.20M | $ -8.02M | $ -3.59M | $ 7.44M | $ -1.17M |
| Total Liabilities | $ 69.73M | $ 105.21M | $ 91.14M | $ 98.48M | $ 93.31M |
| Stockholders' Equity | $ 35.27M | $ 18.97M | $ 27.72M | $ 39.36M | $ 44.31M |
| Cash Flow | |||||
| Free Cash Flow | $ 3.25M | $ -5.17M | $ -1.72M | $ -5.13M | $ -28.82M |
| Operating Cash Flow | $ 3.28M | $ -1.94M | $ -1.39M | $ -5.13M | $ -28.82M |
| Investing Cash Flow | $ -29.00K | $ -2.56M | $ -329.00K | $ -117.00K | $ -3.25M |
| Financing Cash Flow | $ -7.90M | $ 15.44M | $ -1.26M | $ 8.87M | $ 1.53M |
Currency in USD